Corruption and Research Fraud Send Big Chill Through Big Pharma in China

See allHide authors and affiliations

Science  02 Aug 2013:
Vol. 341, Issue 6145, pp. 445-446
DOI: 10.1126/science.341.6145.445

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Last month, the Chinese government accused GlaxoSmithKline (GSK) of bribing officials and others to ease GSK drug sales. With four executives in prison, the ongoing investigation may jeopardize big pharma's burgeoning R&D operations in China. But while multinationals may consider stricter controls on their China operations, few expect the companies to pull out of the growing market.